Representatives from industry associations, companies and governing bodies yesterday said that while it is vital for the nation to participate in the Trans-Pacific Partnership (TPP) and the Regional Comprehensive Economic Partnership (RCEP), Taiwan’s biotechnology, medical and pharmaceutical sectors must first overcome several challenges before they have a chance of tapping international markets.
Taiwan’s accession to the TPP and RCEP would improve international harmonization on regulatory approval guidelines and allow the nation’s top biotechnology, pharmaceutical, and medical products and services to enter international marketplaces, experts said at a forum in Taipei.
Taiwanese companies would enjoy reduced costs of entry and risks thanks to greater levels of transparency in regulatory approval processes and assessment metrics, which are awarded to members of the trade blocs, panelists said.
As the nation vies to increase exports of active pharmaceutical ingredients and boost new drug development, which is currently estimated at less than 1 percent of the global market, domestic generic drug makers would face greater challenges, such as the more stringent intellectual property and patent laws in major markets abroad, Vice Premier Simon Chang (張善政) said.
“Due to immense development costs of developing new drugs, companies’ research findings must be protected by comprehensive patent systems to ensure their first-to-market advantage,” Savior Lifetec Corp (展旺生命科技) chairperson Sherry Ku (顧曼芹) said.
The concept of patent linkage, which prevents generic drugs from obtaining market licenses prior to the expiration of the patent term or receiving the consent of the original manufacturer is recognized in law in a number of major markets, including the US and India, and would likely be one of the conditions of joining the TPP, Ku said.
However, few Taiwanese companies are equipped to navigate the complex patent systems and obtain the required certifications, Ku said.
Taiwan’s lack of a patent linkage system has deterred foreign companies interested in the nation.
“Companies must adopt different strategies for each trade block. While innovation is vital for success in the TPP, where demand is higher for medications for mental illnesses, cost effectiveness is key in the RCEP, where the demand is focused on treating infectious diseases,” ScinoPharm Taiwan Ltd (台灣神隆) cofounder Hardy Chan (詹維康) said.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Microsoft Corp yesterday said that it would create Thailand’s first data center region to boost cloud and artificial intelligence (AI) infrastructure, promising AI training to more than 100,000 people to develop tech. Bangkok is a key economic player in Southeast Asia, but it has lagged behind Indonesia and Singapore when it comes to the tech industry. Thailand has an “incredible opportunity to build a digital-first, AI-powered future,” Microsoft chairman and chief executive officer Satya Nadella said at an event in Bangkok. Data center regions are physical locations that store computing infrastructure, allowing secure and reliable access to cloud platforms. The global embrace of AI
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San